Attenuating effect of Lactobacillus brevis G101 on the MSG symptom complex in a double-blind, placebo-controlled study

BACKGROUND/OBJECTIVES: Lactobacillus brevis G101 suppresses the absorption of monosodium glutamate (MSG) from the intestine into the blood in mice. Therefore, the attenuating effect of orally administered G101 on monosodium glutamate (MSG) symptom complex was investigated in humans MATERIALS/METHODS...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition research and practice 2015, 9(6), , pp.673-676
Main Authors: Kim, D.H., Kyung Hee University, Seoul, Republic of Korea, Choi, Y., Kyung Hee University, Seoul, Republic of Korea, Park, S.S., Kyung Hee University, Seoul, Republic of Korea, Kim, S.Y., R and D center, CTCBIO Inc., Ansan, Republic of Korea, Han, M.J., Kyung Hee University, Seoul, Republic of Korea
Format: Article
Language:English
Subjects:
ACIDE GLUTAMIQUE
ACIDO GLUTAMICO
GLUTAMIC ACID
Short Communication
side effect,Lactobacillus brevis G10,blind study
생활과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND/OBJECTIVES: Lactobacillus brevis G101 suppresses the absorption of monosodium glutamate (MSG) from the intestine into the blood in mice. Therefore, the attenuating effect of orally administered G101 on monosodium glutamate (MSG) symptom complex was investigated in humans MATERIALS/METHODS: Capsules (300 mg) containing Lactobacillus brevis G101 (1 x 1010 CFU/individual) or maltodextrin (placebo) was orally administered in 30 respondents with self-recognized monosodium glutamate (MSG) symptom complex for 5 days and the rice with black soybean sauce containing 6 g MSG (RBSM) was ingested 30 min after the final administration. Thereafter, the MSG symptom complex (rated on a 5-point scale: 1, none; 5, strong) was investigated in a double blind placebo controlled study. The intensity of the MSG symptom complex was significantly reduced in respondents of the G101 intake group (2.87 + - 0.73) compared to that in those treated with the placebo (3.63 + - 1.03) (P = 0.0016). Respondents in the placebo group exhibited more of the various major conditions of the MSG symptom complex than in the G101 intake group. Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P
ISSN:1976-1457
2005-6168
DOI:10.4162/nrp.2015.9.6.673